Literature DB >> 30003391

Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors.

Jefferson da Rocha Tenório1, Leorik Pereira da Silva2, Marília Gabriela de Aguiar Xavier3, Thalita Santana4, George João Ferreira do Nascimento5, Ana Paula Veras Sobral3.   

Abstract

PURPOSE: Salivary gland tumors are complex and have a great histomorphological diversity; more than 30 histological subtypes are currently described and the study of proteins that help understand and differentiate these tumors is essential. We aimed to analyze the immunoexpression of cyclooxygenase-2 (COX-2) and cyclin D1 proteins in pleomorphic adenomas (PA), mucoepidermoid carcinomas (MEC) and adenoid cystic carcinomas (AdCC) of salivary glands.
METHODS: A total of 38 PA, 12 AdCC and 12 MEC underwent immunohistochemical study by the polymeric biotin-free technique. Immunopositive cells were analyzed semi-quantitatively. For statistical analysis, a significance level was set at p ≤ 0.05.
RESULTS: Overall, these tumors were more prevalent in women (n = 37). The mean age of these patients was 58-year-old and the parotid gland was the most affected anatomic site (n = 33). All cases of AdCC and MEC showed immunopositivity to cyclin D1; however, 39.5% of the PAs were negative (p < 0.001). Regarding COX-2 immunoexpression, we observed that all cases of CME were positive, whereas 60.5% of the PA and 75% of the CAC analyzed were completely negative (p = 0.042).
CONCLUSIONS: The overexpression of COX-2, observed only in MEC, emphasizes that salivary gland tumors have different profiles. Cyclin D1 is more immunoexpressed in malignant tumors. Together, these immunohistochemical findings may be useful in differentiating the studied tumors.

Entities:  

Keywords:  Cell cycle; Immunohistochemistry; Inflammation; Salivary gland tumors

Mesh:

Substances:

Year:  2018        PMID: 30003391     DOI: 10.1007/s00405-018-5058-5

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  31 in total

1.  The prognostic significance of cyclin D1 expression in patients with triple-negative breast cancer.

Authors:  Betul Bolat Kucukzeybek; Ibrahim Vedat Bayoglu; Yuksel Kucukzeybek; Ahmet Alacacioglu; Seyran Yigit; Aysegul Akder Sari; Murat Akyol; Mustafa Oktay Tarhan
Journal:  J BUON       Date:  2017 Jul-Aug       Impact factor: 2.533

2.  Overexpressions of Cyclin B1, cdc2, p16 and p53 in human breast cancer: the clinicopathologic correlations and prognostic implications.

Authors:  Seoung Wan Chae; Jin Hee Sohn; Dong-Hoon Kim; Yoon Jung Choi; Yong Lai Park; Kyungeun Kim; Young Hye Cho; Jung-Soo Pyo; Jun Ho Kim
Journal:  Yonsei Med J       Date:  2011-05       Impact factor: 2.759

3.  Expression of cyclooxygenase-2, peroxiredoxin I, peroxiredoxin 6 and nuclear factor-κB in oral squamous cell carcinoma.

Authors:  Eun-Young Lee; Ji-Yeon Kang; Kyoung-Won Kim
Journal:  Oncol Lett       Date:  2015-09-16       Impact factor: 2.967

4.  Differential expression of p16(INK4A) and cyclin D1 in benign and malignant salivary gland tumors: a study of 44 Cases.

Authors:  G Jour; K West; V Ghali; D Shank; G Ephrem; B M Wenig
Journal:  Head Neck Pathol       Date:  2013-01-13

5.  Celecoxib inhibits cell growth and modulates the expression of matrix metalloproteinases in human osteosarcoma MG-63 cell line.

Authors:  X Zhou; X Shi; K Ren; G-T Fan; S J Wu; J-N Zhao
Journal:  Eur Rev Med Pharmacol Sci       Date:  2015-11       Impact factor: 3.507

6.  Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis.

Authors:  Shishir Shishodia; Dimpy Koul; Bharat B Aggarwal
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

7.  Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms.

Authors:  B Liu; J K Wen; B H Li; X M Fang; J J Wang; Y P Zhang; C J Shi; D Q Zhang; M Han
Journal:  Cell Death Dis       Date:  2011-07-28       Impact factor: 8.469

8.  MTA1 Expression in Benign and Malignant Salivary gland Tumors.

Authors:  Azadeh Andisheh-Tadbir; Ali Dehghani-Nazhvani; Mohammad Javad Ashraf; Bijan Khademi; Hosein Mirhadi; Shima Torabi-Ardekani
Journal:  Iran J Otorhinolaryngol       Date:  2016-01

Review 9.  Cyclooxygenase-2: A Role in Cancer Stem Cell Survival and Repopulation of Cancer Cells during Therapy.

Authors:  Lisa Y Pang; Emma A Hurst; David J Argyle
Journal:  Stem Cells Int       Date:  2016-11-01       Impact factor: 5.443

10.  Cyclooxygenase-2 expression and its prognostic significance in clear cell renal cell carcinoma.

Authors:  Ji Won Lee; Jeong Hwan Park; Ja Hee Suh; Kyung Han Nam; Ji-Young Choe; Hae Yoen Jung; Ji Yoen Chae; Kyung Chul Moon
Journal:  Korean J Pathol       Date:  2012-06-22
View more
  1 in total

Review 1.  Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis.

Authors:  Ellen Frejborg; Tuula Salo; Abdelhakim Salem
Journal:  Int J Mol Sci       Date:  2020-12-03       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.